Changes To UK Price Scheme To Hit Profits, Biosimilar Launches
Executive Summary
Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.
You may also be interested in...
UK Price Scheme Changes To Cost Pharmaceutical Industry £33m
The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.